ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq
This article was originally published in The Pink Sheet Daily
Institute for Clinical and Economic Review aims to complete cost effectiveness analysis of non-small lung cancer drugs in time for supplemental approval of the newest PD-L1 inhibitor in the space.
You may also be interested in...
ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.